Early versus delayed follow-up after misoprostol treatment for early pregnancy loss.
Misoprostol
Pregnancy loss
Spontaneous abortion
Journal
Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
18
11
2018
revised:
15
01
2019
accepted:
25
02
2019
pubmed:
27
4
2019
medline:
5
8
2020
entrez:
27
4
2019
Statut:
ppublish
Résumé
Does extending the follow-up after misoprostol treatment for early pregnancy loss increase the success rate? Patients who had experienced early pregnancy loss (<12 weeks) and were treated with misoprostol in a single university-affiliated medical centre were prospectively followed before and after the implementation of a new treatment protocol extending the follow-up from 1 to 2 weeks. All patients received misoprostol 800 μg vaginally on day 1 and a second dose, when needed, on day 4 or 8. Patients underwent surgical aspiration after 1 week in the early follow-up group (n = 84) or 2 weeks in the delayed follow-up group (n = 85) if complete expulsion was not achieved (defined as endometrial thickness ≤15 mm and absence of gestational sac on transvaginal sonography). The primary outcome was treatment success, defined as no need for surgical aspiration. Women in the delayed follow-up group had a higher rate of successful treatment compared with women in the early follow-up group (88.2% versus 76.2%, respectively; P = 0.040), and a lower rate of second dose administration (32.9% versus 51.2%, respectively; P = 0.016). The incidence of non-expulsion of the gestational sac was also lower in the delayed follow-up group (1.2% versus 10.7%; P = 0.009). Treatment acceptability did not differ between the study groups. In women with early pregnancy loss treated with misoprostol, extending the follow-up protocol from 1 to 2 weeks resulted in an increase in treatment success.
Identifiants
pubmed: 31023610
pii: S1472-6483(19)30237-8
doi: 10.1016/j.rbmo.2019.02.011
pii:
doi:
Substances chimiques
Misoprostol
0E43V0BB57
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-160Informations de copyright
Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.